Table of Contents
1
UI - 11954027
AU - Hecht JL; Lee BH; Pinkus JL; Pinkus GS
TI -
The value of Wilms tumor susceptibility gene 1 in cytologic preparations
as a marker for malignant mesothelioma.
SO - Cancer 2002 Apr 25;96(2):105-9
AD - Department of Pathology, Brigham and Women's Hospital, Boston,
Massachusetts 02115, USA.
BACKGROUND: It has been shown that detection of the Wilms tumor
susceptibility gene 1 protein (WT1) has diagnostic utility in the
distinction of mesothelioma from adenocarcinoma in tissue sections of
pleural tumors. This immunohistochemical study evaluates the
effectiveness of WT1 as a marker for malignant mesothelioma in paraffin
sections of cell block preparations derived from effusion specimens.
METHODS: The authors evaluated 111 cell blocks for WT1 immunoreactivity,
including 14 mesotheliomas and 97 metastatic adenocarcinomas from
various sites. RESULTS: Nuclear reactivity for WT1 was observed in all
samples of mesothelioma. However, only 22 of 97 samples (23%) of
metastatic adenocarcinoma, nearly all of which were of ovarian origin
(91%), exhibited nuclear reactivity for WT1. In 14 other samples (most
of pulmonary derivation), WT1 staining restricted to the cytoplasm was
observed for some tumor cells and was regarded as nonspecific.
CONCLUSIONS: Based on this staining profile, WT1 represents an effective
marker for mesotheliomas in cell block preparations and can aid in its
distinction from pulmonary adenocarcinoma. In assessment of effusion
specimens with metastatic carcinoma, nuclear reactivity for WT1 is
highly suggestive of an ovary primary tumor Copyright 2002 American
Cancer Society.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home